Clinical trials: Advanced Cancer
Renal Cell Carcinoma
Clinical Outcome Of Advanced Renal Cell Carcinoma In Taiwan
The clinical outcome of advanced / metastatic renal cell carcinoma has been changed since targeted therapy being widely applied.
- Trial name
- NCT02776644
- Volunteers
- 1,349 people
- Sponsor
- Pfizer
Advanced Cancer
Sirolimus or Everolimus or Temsirolimus and Vorinostat in Advanced Cancer
The goal of this clinical research study is to find the highest tolerable dose of the combination vorinostat given in combination with either sirolimus, everolimus or temsirolimus that can be given to patients with advanced…
- Trial name
- NCT01087554
- Testing
- Sirolimus, Vorinostat, Everolimus
- Where
- United States
- Volunteers
- 249 people
- Sponsor
- M.D. Anderson Cancer Center
Metastatic Breast Cancer
Multicenter Follow Up Study Of Subjects Who Participated In An Original Protocol Of Exemestane Vs. Megestrol Acetate In Postmenopausal Women With Metastatic Breast Cancer
Long term efficacy of exemestane as compared to megestrol acetate in the treatment of women with natural or induced postmenopausal status with advanced breast cancer whose disease has progressed following anti-estrogens or…
- Trial name
- NCT01237327
- Testing
- Megestrol acetate, exemestane (Aromasin)
- Where
- 7 sites in China
- Volunteers
- 84 people
- Sponsor
- Pfizer
Soft Tissue Sarcoma (Excluding GIST)
Liposomal Irinotecan in Combination With Temozolomide and Bevacizumab in Patients With Advanced STS
The study is expected to include 24 patients with metastatic or surgically unresectable relapsed/refractory soft tissue sarcoma confirmed by histological evidence, who have received at least one line of systemic treatment…
- Trial name
- NCT07457775
- Testing
- Irinotecan Hydrochloride Liposome Injection(II) combined with temozolomide and bevacizuma
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Metastatic Breast Cancer, HER2-negative Breast Cancer
Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.
Phase 1b/2 open-label trial of 225Ac-DOTATATE (RYZ101) in subjects with ER+, HER2-negative unresectable or metastatic breast cancer expressing SSTRs.
- Conditions
- Metastatic Breast Cancer, HER2-negative Breast Cancer, ER+ Breast Cancer, Advanced Breast Cancer
- Trial name
- TRACY-1 (NCT06590857)
- Testing
- RYZ101, Standard of Care Endocrine Therapy
- Where
- 31 sites in United States, Canada and 1 more
- Volunteers
- 64 people
- Sponsor
- RayzeBio, Inc.
Cancer, Solid Tumor
Oral AMXT 1501 Dicaprate in Combination With DFMO
A Phase 1 study will be conducted to establish safety and dose level of AMXT 1501 dicaprate alone, and in combination with DFMO, in cancer patients.
- Conditions
- Cancer, Solid Tumor, Solid Carcinoma, Advanced Cancer
- Trial name
- NCT03536728
- Testing
- AMXT1501, DFMO
- Where
- 4 sites in United States
- Volunteers
- 56 people
- Sponsor
- Aminex Therapeutics, Inc.
Liver Cancer, Metastatic Cancer
Heat Therapy in Treating Patients With Unresectable Primary or Metastatic Liver Cancer
RATIONALE: Heating tumors to several degrees above body temperature may kill tumor cells. PURPOSE: Phase II trial to study the effectiveness of heat therapy in treating patients who have unresectable primary or metastatic liver…
- Trial name
- NCT00004136
- Testing
- Radiofrequency Ablation
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- M.D. Anderson Cancer Center
Soft Tissue Sarcoma (STS), Osteosarcoma
Cryoablation Plus Camrelizumab for Advanced Soft Tissue Sarcoma
The main purpose of this trial is to investigate and evaluate the efficacy of cryoablation combined with camrelizumab treatment to patients with advanced or inoperable soft tissue sarcomas after standard treatment failure.
- Trial name
- NCT07602049
- Testing
- Cryoablation therapy + anti-PD-1 antibody
- Where
- China
- Volunteers
- 57 people
- Sponsor
- Sun Yat-sen University
Synovial Sarcoma
A Study of Anti-CTLA-4 Antibody in Patients With Advanced Synovial Sarcoma
The purpose of this study is to determine whether immune therapy with anti-CTLA-4 antibody is effective in people with advanced synovial sarcoma.
- Trial name
- NCT00140855
- Testing
- ipilimumab
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Ludwig Institute for Cancer Research
Ovarian Neoplasm
A Multi-Institutional Phase II Study of Cyclophosphamide, Paclitaxel, Cisplatin With G-CSF for Patients With Newly Diagnosed Advanced Stage Ovarian Cancer
A supra-additive cytotoxic effect was seen when CAI and paclitaxel were given to human ovarian cancer cells sequentially in tissue culture.
- Trial name
- NCT00001426
- Testing
- Cyclophosphamide, Paclitaxel, Cisplatin
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- National Cancer Institute (NCI)
Malignant Neoplasm
Cixutumumab and Temsirolimus in Treating Patients With Locally Advanced or Metastatic Cancer
This phase I trial studies the side effects and best dose of cixutumumab and temsirolimus in treating patients with locally advanced or metastatic cancer.
- Trial name
- NCT00678769
- Testing
- Cixutumumab, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 2 sites in United States
- Volunteers
- 72 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Cancers, Solid Tumors
Pazopanib and Everolimus in PI3KCA Mutation Positive/PTEN Loss Patients
The goal of this clinical research study is to find the highest tolerable dose of the combination of Votrient (pazopanib) and Afinitor (everolimus) that can be given to patients with advanced cancer.
- Trial name
- NCT01430572
- Testing
- Pazopanib, Everolimus
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- M.D. Anderson Cancer Center
Sarcoma
A Study to Provide Access to Trabectedin in Participants With Locally Advanced or Metastatic Soft Tissue Sarcoma Who Have Persistent or Recurrent Disease and Who Are Not Expected to Benefit From Currently Available Standard of Care Treatment
The purpose of this study is to facilitate access to trabectedin for eligible previously treated patients with soft tissue sarcoma (STS), who cannot be expected to benefit from currently available therapeutic options but who may…
- Trial name
- NCT00210665
- Testing
- Trabectedin
- Where
- 36 sites in United States, Canada and 1 more
- Sponsor
- Janssen Research & Development, LLC
Sarcoma
MAGNATE-S: Paclitaxel Polymer Micelles Combo in Advanced Sarcoma
What is this study about? This is a medical research study testing a new drug combination ("Paclitaxel Polymer Micelles" + "Gemcitabine" + "Targeted Therapy") for patients with locally advanced unresectable or metastatic bone and…
- Trial name
- MAGNATE-S (NCT07359053)
- Testing
- Paclitaxel Polymer Micelles + Gemcitabine + Lenvatinib, Paclitaxel Polymer Micelles + Gemcitabine + Anlotinib
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Shanghai 6th People's Hospital
Metastatic Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v8
Utomilumab, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Metastatic Colorectal Cancer
This phase I trial studies the best dose and side effects of irinotecan hydrochloride when given with utomilumab and cetuximab in treating patients with colorectal cancer that has spread to other places in the body (metastatic).
- Conditions
- Metastatic Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8
- Trial name
- NCT03290937
- Testing
- Cetuximab, Irinotecan Hydrochloride, Pharmacodynamic Study
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- M.D. Anderson Cancer Center
Ovarian Neoplasms
A Phase II Trial of 72-Hour Continuous IV Infusion of 9-Aminocamptothecin With G-CSF Support in Patients With Advanced Ovarian Cancer Previously Treated With Paclitaxel and Cisplatin
The objectives of this study are to determine the response rate to 9-AC in patients with advanced ovarian cancer who have recurrent disease after paclitaxel- and cisplatin-based chemotherapy regimens.
- Trial name
- NCT00001427
- Testing
- 9-aminocamptothecin
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Brain Tumors, Central Nervous System Tumors
Etoposide Plus Radiation Therapy Followed by Combination Chemotherapy in Treating Children With Newly Diagnosed Advanced Medulloblastoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00003573
- Testing
- filgrastim, cisplatin, cyclophosphamide
- Where
- 106 sites in United States, Canada and 3 more
- Volunteers
- 53 people
- Sponsor
- Children's Oncology Group
Non-Clear Cell Renal Cell Carcinoma
Personalized ctDNA Monitoring for Predicting Immunotherapy Outcomes in Advanced Non-Clear Cell Renal Cell Carcinoma
This is a prospective, non-interventional observational cohort study evaluating the clinical utility of patient-specific circulating tumor DNA (ctDNA) monitoring in patients with advanced non-clear cell renal cell carcinoma…
- Trial name
- NCT07776483
- Testing
- Patient-Specific Tumor-Informed ctDNA Monitoring
- Volunteers
- 67 people
- Sponsor
- West China Hospital
Melanoma (Skin)
Combination Chemotherapy Plus Biological Therapy in Treating Patients With Metastatic Melanoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Biological therapies use different ways to stimulate the immune system and stop cancer cell from growing.
- Trial name
- NCT00004141
- Testing
- Cisplatin, dacarbazine, Granulocyte-macrophage colony-stimulating factor
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- University of Chicago
Stage IIIA Ovarian Cancer, Stage IIIB Ovarian Cancer
Study of Tumor Tissue Samples From Patients Who Have Undergone Surgery for Advanced Stage III or Stage IV Ovarian Epithelial Cancer
This research study is looking at tumor tissue samples from patients who have undergone surgery for advanced stage III or stage IV ovarian epithelial cancer.
- Conditions
- Stage IIIA Ovarian Cancer, Stage IIIB Ovarian Cancer, Stage IIIC Ovarian Cancer, Stage IV Ovarian Cancer
- Trial name
- NCT01000259
- Testing
- Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 174 people
- Sponsor
- Gynecologic Oncology Group
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.